NDA 022260 · Actelion
Veletri
Epoprostenol Sodium · Injection · Prostacycline Vasodilator
Last checked: Nov 20, 2026Latest source record: Oct 21, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Jun 27, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
92
18 Phase 3, 9 recruiting
FAERS reports
13,102
11,321 serious, 2,715 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 28, 2022.
VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. VELETRI is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. ( 1 )
Mechanism: Epoprostenol has 2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 2008 Original approval · Type 5 - New Formulation or New Manufacturer Summary ReviewLetterReview
2 products under this application
- VELETRI · EPOPROSTENOL SODIUM EQ 0.5MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP2
- VELETRI · EPOPROSTENOL SODIUM EQ 1.5MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP2
Clinical trials
Interventional ClinicalTrials.gov studies with "Epoprostenol" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPivotal-lookingEnrolling by invitation
United TherapeuticsIndustry
NCT03683186 · 1,000 participants (planned) · Start Sep 23, 2019 · Primary completion Dec 2026
Drug: Ralinepag · For: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension and 8 more
Sites: Phoenix, Arizona; Tucson, Arizona; La Jolla, California · 190 sites in all
- TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)Pivotal-lookingCompleted
Toray Industries, IncIndustry
NCT01090037 · 892 participants · Start Mar 2010 · Primary completion Aug 2014
Drug: TRK-100STP high dose; TRK-100STP low dose and 1 more · For: Chronic Renal Failure; Glomerular Disease; Nephrosclerosis
Sites: Beijing, China; Hong Kong, Hong Kong; Tokyo, Japan · 7 sites in all
- Tezosentan in Acute Heart FailurePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT00525707 · 735 participants · Start Apr 2003 · Primary completion Jan 2005
Drug: tezosentan · For: Acute Heart Failure; Acute Decompensation of Chronic Heart Failure; New Onset of Heart Failure
Sites: Birmingham, Alabama; Palo Alto, California; Denver, Colorado · 35 sites in all
- Tezosentan in the Treatment of Acute Heart FailurePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT00524433 · 713 participants · Start Apr 2003 · Primary completion Jan 2005
Drug: tezosentan; placebo · For: Acute Heart Failure; Acute Decompensation of Chronic Heart Failure; New Onset of Heart Failure
Sites: Huntsville, Alabama; Los Angeles, California; Jacksonville, Florida · 42 sites in all
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsPivotal-lookingCompleted
United TherapeuticsIndustry
NCT03626688 · 687 participants · Start Jan 24, 2019 · Primary completion Dec 31, 2025
Drug: Ralinepag; Placebo · For: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension and 8 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 209 sites in all
- Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory FailurePivotal-lookingRecruiting
Pär JohanssonAcademic, hospital or other
NCT06319274 · 450 participants (planned) · Start Apr 15, 2024 · Primary completion Sep 30, 2027
Drug: Iloprost; Isotonic saline · For: Acute Respiratory Failure; Endothelial Dysfunction; Pulmonary Infection
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 5 sites in all
- LACunar Intervention (LACI-2) Trial-2Pivotal-lookingCompleted
University of EdinburghAcademic, hospital or other
NCT03451591 · 363 participants · Start Jan 8, 2018 · Primary completion May 31, 2022
Drug: Isosorbide Mononitrate XL (ISMN); Cilostazol and 1 more · For: Cerebral Small Vessel Diseases; Stroke, Lacunar
Sites: Edinburgh, United Kingdom
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)Pivotal-lookingCompleted
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
NCT04576988 · 324 participants · Start Jan 25, 2021 · Primary completion Aug 26, 2022
Drug: Sotatercept; Placebo and 1 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; San Diego, California · 120 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea2,785
- headache2,302
- diarrhoea2,178
- nausea1,970
- pain in jaw1,859
- death1,329
- flushing1,174
- fatigue1,117
- pulmonary arterial hypertension1,105
- vomiting1,051
- dyspnoea exertional969
- fluid retention926
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 10 |
| 2006 | 1 |
| 2009 | 24 |
| 2010 | 16 |
| 2011 | 52 |
| 2012 | 328 |
| 2013 | 680 |
| 2014 | 1,381 |
| 2015 | 1,504 |
| 2016 | 1,492 |
| 2017 | 1,275 |
| 2018 | 1,345 |
| 2019 | 1,075 |
| 2020 | 1,006 |
| 2021 | 577 |
| 2022 | 576 |
| 2023 | 447 |
| 2024 | 503 |
| 2025 | 474 |
| 2026 | 331 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Veletri (Epoprostenol Sodium)
2024 spending
$606K
Beneficiaries
22
223 claims
Per beneficiary
$27,530
$52.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $145,811 |
| 2021 | $545,538 |
| 2022 | $742,880 |
| 2023 | $759,548 |
| 2024 | $605,651 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Prostacyclin for pulmonary hypertension.
Paramothayan NS, Lasserson TJ, Wells AU, et al. · Cochrane Database Syst Rev 2003 · Systematic Review
- Prostacyclin for pulmonary hypertension.
Paramothayan NS, Lasserson TJ, Wells AU, et al. · Cochrane Database Syst Rev 2002 · Systematic Review
- Long-term treatment of pulmonary hypertension with aerosolized iloprost.
Machherndl S, Kneussl M, Baumgartner H, et al. · Eur Respir J 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
Ghadimi K, Cappiello JL, Wright MC, et al. · Circulation 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Ischemic Preconditioning Improves Microvascular Endothelial Function in Remote Vasculature by Enhanced Prostacyclin Production.
Rytter N, Carter H, Piil P, et al. · J Am Heart Assoc 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.